Sakar Healthcare Reports 95% Surge in Q1 Net Profit, EBITDA Grows Despite Margin Decline Jul 25, 2025
Sakar Healthcare Expands European Footprint with New Anti-Cancer Injection Approvals Jul 16, 2025
More news about Sakar Healthcare
18Jun 25
Sakar Healthcare Eyes EU Expansion with Anticipated MAS Approval for Oncology Products
Sakar Healthcare Ltd expects to receive Marketing Authorization System (MAS) approval for its oncology products in the European Union (EU) over the coming months. The company has already secured its second marketing authorization for an oncology injection in the EU. These approvals are expected to significantly boost Sakar's export capabilities to the EU market, potentially increasing its global footprint and revenue streams. The gradual approval process reflects the company's strategic focus on the oncology segment and its efforts to expand in the European pharmaceutical market.
Sakar Healthcare Ltd has released its Q4 FY23 financial results, showing significant year-over-year improvements. Net profit increased by 87.10% to ₹58.00 crore, while revenue grew by 16.74% to ₹502.00 crore. EBITDA rose by 42.73% to ₹157.00 crore, with the EBITDA margin expanding by 583 basis points to 31.30%. These results demonstrate strong performance across all key financial metrics, indicating robust demand for the company's products and improved operational efficiency.
21Apr 25
Sakar Healthcare Achieves First EU Marketing Authorization for Oncology Injection
Sakar Healthcare Ltd has obtained its first Marketing Authorization (MA) in the European Union for an oncology injection. This approval marks a significant milestone in the company's international expansion, opening up opportunities in the European oncology market. The authorization demonstrates Sakar's ability to meet EU regulatory standards and strengthens its oncology product portfolio.
16Apr 25
Sakar Healthcare Expands Global Reach with 9 New Export Agreements
Sakar Healthcare Ltd has signed nine strategic agreements with partners in Europe and South America for exporting oncology products. This move marks a significant step in the company's global expansion strategy, particularly in the oncology segment. While financial details are undisclosed, the partnerships are expected to boost export volumes and revenue, diversify market presence, and strengthen the company's position in the specialized pharmaceutical market.